The group’s research focuses on understanding the molecular mechanisms that endow tumor cells with adaptive cellular plasticity in the context of acquired drug resistance. The goal is to determine new avenues of therapeutic intervention to improve our ability to treat aggressive cancers.
The group is part of the Center for Cancer Biomarkers, CCBIO at the Departments of Biomedicine and Department of Clinical Medicine at the University of Bergen, and of the Metabolism and Cancer research unit at the Department of Biomedicine.
Principal Investigator
The group is headed by professor James Lorens (visit his personal page).